Sitagliptin Vildagliptin And Saxagliptin Dipeptidyl Peptidase

PDF
Sitagliptin, vildagliptin and saxagliptin — dipeptidyl ...

Sitagliptin, vildagliptin and saxagliptin — dipeptidyl ...

Sitagliptin, vildagliptin and saxagliptin NPS RADAR | FEBRUARY 2013 NPS Better choices Better health 4 How does it compare? Gliptins improve glycaemic control in patients
Mon, 15 Dec 2014 00:56:00 GMT
Synthesis of (S)-1-(2-chloroacetyl)pyrrolidine-2 ...

Synthesis of (S)-1-(2-chloroacetyl)pyrrolidine-2 ...

Beilstein Journal of Organic Chemistry 2008, 4, No. 20. Page 3 of (page number not for citation purposes) 5 Scheme 3: Preparation of Vildagliptin (2).
Thu, 18 Dec 2014 02:04:00 GMT
Saxagliptin for the treatment of type 2 diabetes mellitus ...

Saxagliptin for the treatment of type 2 diabetes mellitus ...

REVIEW Open Access Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data Michael E Cobble1* and Robert Frederich2
Thu, 18 Dec 2014 07:26:00 GMT
Stellungnahme der Deutschen Diabetes Gesellschaft (DDG) zu ...

Stellungnahme der Deutschen Diabetes Gesellschaft (DDG) zu ...

kritische und fachübergreifende Stellungnahme zusammen mit der Deutschen Gesellschaft für Innere Medizin (DGIM), der Deutschen Gesellschaft für Kardiologie (DGK ...
Tue, 16 Dec 2014 16:04:00 GMT
New Drugs in Development for the Treatment of Diabetes

New Drugs in Development for the Treatment of Diabetes

92 Diabetes Spectrum Volume 22, Number 2, 2009 In Brief A variety of new agents are in development for the treatment of type 1 or type 2 diabetes.
Wed, 17 Dec 2014 22:44:00 GMT
Comparison of efficacy between incretin-based therapies ...

Comparison of efficacy between incretin-based therapies ...

comparative trials analyzing efficacy, tolerability and safety profiles between the agents from these two classes. Physiology of incretins The classic ‘incretin ...
Mon, 15 Dec 2014 12:59:00 GMT
Launch Excellence in the Diabetes Market - Home - IMS Health

Launch Excellence in the Diabetes Market - Home - IMS Health

IMS HEALTH |LAUNCH EXCELLENCE IN THE DIABETES MARKET 5 WHITE PAPER |DIABETES LAUNCH EXCELLENCE The competitive success of ...
Mon, 15 Dec 2014 19:33:00 GMT
CHMP ASSESSMENT REPORT FOR Onglyza - European Medicines Agency

CHMP ASSESSMENT REPORT FOR Onglyza - European Medicines Agency

Page 5 of 57 2 SCIENTIFIC DISCUSSION 2.1 Introduction Type 2 Diabetes Mellitus (T2DM) is a common chronic metabolic disorder, which can lead to
Thu, 18 Dec 2014 00:10:00 GMT
Linagliptin: new DPP-4 inhibitor for type 2 diabetes mellitus

Linagliptin: new DPP-4 inhibitor for type 2 diabetes mellitus

Type 2 diabetes mellitus (T2DM) is a chronic disorder charac - terised by progressive decline in beta cell function and insulin resist-ance leading to deterioration ...
Thu, 18 Dec 2014 06:58:00 GMT
Synthesis of a novel analogue of DPP-4 inhibitor ...

Synthesis of a novel analogue of DPP-4 inhibitor ...

Beilstein J. Org. Chem. 2010, 6, No. 71. Page 3 of (page number not for citation purposes) 5 Scheme 1: Reagents and conditions: (i) EtONa, BrCH2CH2Br, EtOH, reflux, 3 ...
Mon, 15 Dec 2014 17:17:00 GMT